'Pluck­ing our way up that list': Bay­er high­lights on­col­o­gy am­bi­tions in new Kendall Square labs

It’s been just a few months since Bay­er opened its new $140 mil­lion on­col­o­gy re­search and in­no­va­tion cen­ter in Cam­bridge, MA, just down the road from its old Kendall Square digs. Now it’s all hands on deck to beef up the pipeline — and that means deals are com­ing, ac­cord­ing to glob­al on­col­o­gy head Chris­tine Roth.

Though the phar­ma gi­ant is still hold­ing its cards close to the vest, Roth told End­points News on Wednes­day that she’s most in­ter­est­ed right now “in that Phase I-plus space.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER